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costs ($14,380 vs. $9,800 respectively, p≤0.05). CONCLUSIONS: Diabetes patients 
with consistently high medication adherence to oral medications or having a 
history of an HbA1c test over a five-year period had lower medical costs and 
lower inpatient and emergency room costs than their counterparts.  
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OBJECTIVES: This study examined the demographics, comorbidities, clinical 
characteristics, and treatments of people with T2DM and an elderly subgroup. 
Additionally, attainment of quality goals and its correlation with diabetes-related 
costs were assessed. METHODS: Health insurance claims and electronic medical 
records from 14,532 adults with T2DM (2007-2011) were used to identify a sample 
receiving MET+SU. The index date was defined as the first dispensing of MET+SU 
after 6 months of eligibility. Clinical characteristics were assessed during 
baseline and quality measure attainment, defined as no values above specific 
thresholds (HbA1c <8%, body mass index [BMI] <30 kg/m2, blood pressure [BP] 
<140/90 mmHg, low-density lipoprotein cholesterol [LDL-C] <100 mg/dL), was 
evaluated during a 12-month landmark period after the index date. Association 
between quality measure attainment and diabetes-related costs, calculated after 
the landmark period, was evaluated using non-parametric bootstrap methods 
adjusting for imbalance in baseline characteristics between cohorts. RESULTS: 
2,044 patients (mean age: 67 years; female: 46%), including 1,283 (62.8%) patients 
≥65 years, were identified. Baseline comorbidities included cardiovascular 
disease (all patients: 25.5%; ≥65 years: 33.4%), congestive heart failure (5.9%; 
8.1%), hypertension (66.5%; 74.2%), hyperlipidemia (73.9%; 78.1%), and 
neuropathy (16.0%; 20.2%). Statins and loop and non-loop diuretics were taken by 
60.5%, 10.5%, and 21.1% of all patients, and 66.9%, 13.8%, and 24.5% of patients 
≥65 years, respectively. The proportions meeting various quality goals were: 
82.9% (≥65 years: 88.2%) for HbA1c, 34.4% (42.1%) for BMI, 31.6% (27.7%) for BP, 
and 68.2% (73.3%) for LDL-C. Quality measure attainment was associated with 
significantly lower diabetes-related costs per-patient per-year (adjusted mean 
cost differences: -$1,445 for HbA1c; -$1,218 for BMI; -$2,029 for HbA1c and BMI;  
-$2,073 for HbA1c, BMI, and BP; all P<0.05) compared to non-attainment. 
CONCLUSIONS: This study highlights the high incidence of comorbidities and 
potential financial benefits of attaining T2DM quality outcomes at the population 
level.  
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OBJECTIVES: To characterize type 2 diabetes mellitus (T2DM) patients’ newly 
initiating insulin therapy with an insulin pen and quantify their health resource 
utilization (HRU). METHODS: Adult patients with at least one new claim for an 
insulin pen between January 2006 and September 2010 were selected from the 
Truven Health MarketScan Research Databases. Patients required continuous 
enrollment for 12 months after the index insulin pen claim, with a diagnosis of 
T2DM and one prescription for an oral antidiabetic drug. Frequency and cost of 
health care encounters were highlighted. HRU includes inpatient admissions, 
emergency department and outpatient office visits, outpatient laboratory and 
radiology services, other outpatient services and outpatient prescriptions. HRU was 
calculated separately for all-cause and diabetes-related expenditures. RESULTS: 
Nine thousand two hundred and eighty five patients met the study criteria with 
average age of 58.5 (SD=12.4); 52.9% were male. The Deyo-Charlson comorbidity 
score for this sample was 2.3 (SD=1.8). Most frequently observed baseline 
microvascular and macrovascular complications included diabetic neuropathy 
(14.7%), renal disease (16.2%), and ischemic heart disease (22.9%). Other common 
comorbidities included hypertension (47.3%) and dyslipidemia (31.5%). Patients 
frequently continued to fill oral anti-diabetic prescriptions after initiating an insulin 
pen, most commonly biguanides (46.3%) or sulfonylureas (31.8%). Concomitant 
medication use was high: most patients (83.9%) used a hypertensive, dyslipidemia 
(72.7%), anti-depressant (28.7%), or anti-emetic/nausea (9.6%) medication in the year 
after insulin pen initiation. In the year after insulin pen initiation, all-cause 
expenditures averaged $26,193 (SD=$47,670)), of which 15.8% were diabetes-related. 
Inpatient admissions accounted for 27.3% of total costs. Medication costs were 
substantial, accounting for 27.6% of total costs; 39.8% of medication costs were 
diabetes-related. CONCLUSIONS: Health expenditures associated specifically with 
T2DM patients initiating an insulin pen are substantial. Further research is required 
to explore the relationship of T2DM medication management on overall health 
resource utilization.  
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OBJECTIVES: To assess level of polypharmacy in patients with type 2 diabetes 
mellitus (T2DM) and its association with adherence to oral anti-diabetic drugs 
(OAD) and health care costs. METHODS: The Thomson MarketScan Commercial 
and Laboratory Databases 2005-2012 were used to select T2DM patients aged 18-
64 with continuous enrollment ≥2 years (the first year as baseline) who used 
OADs. Prescriptions at baseline year with at least 90 days of cumulative days-of-
supply were counted to determine level of polypharmacy according to active 
ingredient. Patients were categorized into four cohorts: no polypharmacy (≤2 
drugs), minor (3-5 drugs), moderate (6-8 drugs), and major (≥9 drugs). Adherence 
to OADs was evaluated during 12-months follow-up using mean proportion of 
days covered (PDC). Adjusted association between polypharmacy and adherence 
(PDC ≥0.8) to OAD and total health care costs were examined using logistic 
regressions and generalized linear regression models, respectively. RESULTS: Of 
the total sample population (N=13,365), 22.4% had non-polypharmacy, 39.3% had 
minor, 25.3% had moderate, and 13.0% had major polypharmacy. The 
polypharmacy cohorts had significantly higher all-cause health care costs (non-
polypharmacy: $7,482; minor: $9,144; moderate: $14,465; major: $25,072; all 
p<0.05) and adherence to OADs (non-polypharmacy: 42.0%; minor: 63.1%; 
moderate: 73.9%; major: 78.3%; all p<0.05) during the post-index period 
compared to non-polypharmacy. Annual incremental costs associated with 
polypharmacy were $1,602 (minor), $5,808 (moderate), and $13,447 (major) when 
compared with non-polypharmacy cohort. A higher level of polypharmacy was 
associated with a higher likelihood of adherence than the non-polypharmacy 
cohort (minor: OR=2.18, 95% CI=1.99-2.40; moderate: OR=3.58, 95% CI=3.20-3.99; 
major: OR=4.70, 95% CI=4.07-5.43). CONCLUSIONS: Polypharmacy was common 
and associated with high economic burden among patients with T2DM. The 
positive association between polypharmacy and adherence to OAD warrants 
further investigation of the behavioral mechanism.  
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OBJECTIVES: The primary objective was to assess the prevalence of DPN using 
Vibration Perception Threshold (VPT) using biothesiometer considered as the 
gold standard for the diagnosis of DPN. The secondary objectives of the study 
were to compare the prevalence between Known Diabetics (KD) and Newly 
Detected Diabetics (NDD), assess the neuropathy prevalence pattern and identify 
any modifiable risk factors associated with occurrence of DPN among diabetics. 
METHODS: The study was cross-sectional, observational study. Subjects were 
recruited from Endocrinology clinic of a public tertiary care hospital. Subjects 
with duration of diabetes (≤6 months) were considered to be NDD. VPT 
measurements were done to assess neuropathy (cut off ≥20V). Severity of 
neuropathy was graded into three groups based on VPT score as mild (20- 24.99 
V), moderate (25-39 V), and severe (>39 V). 791 subjects were included on a 
random sampling basis which includes 638 KD and 153 NDD. Multivariate 
analysis was performed for assessing independent risk factors associated. 
RESULTS: The median duration of diabetes was found to be 6 (2 - 12) years. 300 
subjects were found to have DPN accounting for 37.9% (95%CI: 34.5-41.4) 
prevalence. Higher prevalence was observed in KD compared to ND (43.7% Vs 
13.7%, p<0.001). The prevalence of mild neuropathy was 10.4%, moderate 
neuropathy was 18.9%, and severe neuropathy was 8.6%. Regression analysis has 
shown age (p=0.007), female gender (p=0.001), duration of diabetes (p=0.001), 
dyslipidemia (p=0.008) and presence of other microvascular complication 
(p<0.001) to be associated with DPN occurrence among diabetics. CONCLUSIONS: 
This cross-sectional study shows the prevalence of DPN to be 37.9%. Severe 
neuropathy prevalence was found to be 8.6% who were at the risk of foot 
ulceration or lower limb amputation. DPN was associated significantly with 
increasing age, early onset of diabetes, female gender and dyslipidemia.  
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OBJECTIVES: To study the association between rates of sulfonylurea (SU) use at a 
physician’s practice and average health care costs and complication rates among 
the physician’s patients with type 2 diabetes mellitus (T2DM). METHODS: We 
performed a retrospective group-level analysis on a sample of 7,905 patients 
(214,230 patient-months) insured by Humana, aged 18-64 with an incident T2DM 
diagnosis between 2007 and 2011. We regressed physician-level monthly 
complication rates (cardiovascular, lower extremity, ophthalmic, renal, 
neuropathy, and hypoglycemia) and average health care costs on 3-month-
lagged rates of SU use controlling for use of 10 other T2DM therapy classes in 
each physician’s practice, and patient and practice characteristics. Costs  
were estimated using a generalized linear model with log link to account for 
common zero costs. RESULTS: SU use was associated with increased rates of 
lower extremity, ophthalmic, and renal complications relative to no drug  
use (p<0.05). For each complication class, we identified the best performing 
therapy and estimated the effect of a hypothetical switch in prescribing patterns 
from 100% use of this class to 100% use of SU, as percentages of the respective 
average complication rates. Our estimates were: 93% increase in cardiovascular 
when switching from meglitinides, 133% increase in lower extremity when 
switching from alpha glucosidase inhibitors (AGI), 433% increase in ophthalmic 
when switching from amylinomimetics, 47% increase in renal when switching 
from biguanides, 147% increase in neuropathy when switching from AGIs and 
252% increase in hypoglycemic complications when switching from 
amylinomimetics. Despite SU’s association with higher complication rates, the 
